Loading patent…
AssigneesBayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
InventorsNorbert Schmees, Lars Wortmann, Dennis Kirchhoff, Thi Thanh Uyen Nguyen, Nicolas Werbeck, Ulf Bömer, Kirstin Petersen, Christina Kober, Christian Lechner, Dirk Kosemund, Rienk Offringa, Mareike Grees, Benjamin Bader
Estimating the term…
The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.
A compound having the structure:
A method of treating or preventing a disease or condition associated with dysregulated immune responses or aberrant DGKα signaling in a mammal, comprising administering an effective amount of 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, to the mammal.
Dependencies are inferred from the claim text.